NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals (NASDAQ:DRNA) posted its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.57. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

7 brokerages have issued twelve-month price targets for Dicerna Pharmaceuticals' stock. Their predictions range from $10.00 to $17.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $14.20 in the next year. View Analyst Ratings for Dicerna Pharmaceuticals.

Some companies that are related to Dicerna Pharmaceuticals include Ascendis Pharma A/S (ASND), TESARO (TSRO), Portola Pharmaceuticals (PTLA), Horizon Pharma (HZNP), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Emergent Biosolutions (EBS), The Medicines (MDCO), Global Blood Therapeutics (GBT), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), ACADIA Pharmaceuticals (ACAD), Xencor (XNCR) and Corcept Therapeutics (CORT).

News stories about DRNA stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 0.07 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Dicerna Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include UBS Group AG (1.16%), Artal Group S.A. (0.82%), Millennium Management LLC (0.79%), BlackRock Inc. (0.54%), Citadel Advisors LLC (0.33%) and Spark Investment Management LLC (0.28%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Dicerna Pharmaceuticals.

DRNA stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Citadel Advisors LLC, BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., Element Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $13.77.

Dicerna Pharmaceuticals has a market capitalization of $727.35 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]acbiocom.com.